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Abstract
Background Inflammatory bowel disease (IBD) has a
significant negative impact on quality of life (QOL);
however, the direct impact of IBD on several aspects of
patients’ lives is unknown. The IMPACT survey was
conducted in Europe in 2010–2011 to determine this
impact. We conducted the IMPACT survey in Japan and
compared the results between subgroups of patients with
ulcerative colitis (UC) and Crohn’s disease (CD).
Methods The 52-item IMPACT survey questionnaire
assessing treatment and the impact of IBD on patients’
lives was translated into Japanese and administered to IBD
patients recruited through patient advocacy groups.
Results Between June 2013 and January 2014, 172 Japa-
nese IBD patients completed the questionnaire (including
84 UC and 83 CD patients). Half of all patients (84/172,
48.8 %) were satisfied with their treatment plan, and half of
those who had undergone surgery were satisfied with the
outcome (46/87, 52.9 %). Although 34.9 % (60/172) of
patients had not been hospitalized in 5 years, 50.0 % (86/
172) had been hospitalized for more than 10 days. During
the most recent flare, 49.4 % (85/172) of patients had to
reschedule appointments because of IBD. Moreover,
32.0 % (55/172) of patients had to make adjustments such
as working part-time or at home to avoid taking sick days;
35.5 % (61/172) of patients felt that they had lost a job
because of IBD.
Conclusions Our survey results indicate that IBD patients’
lives and social activities are affected by the deterioration
of QOL due to IBD and its symptoms.
Keywords Inflammatory bowel disease  Quality of life 
Ulcerative colitis  Crohn’s disease  Patient organization
Introduction
Inflammatory bowel disease (IBD) is a group of chronic
and recurring inflammatory conditions of the intestine of
unknown cause and primarily refers to ulcerative colitis
(UC) and Crohn’s disease (CD). As of December 2014 in
Japan, 170,781 patients with UC and 40,885 patients with
CD were receiving treatment, and the number of patients
with IBD is increasing [1]. Because these diseases are
intractable and require long-term therapy, patients undergo
not only physical strain but also deteriorated quality of life
(QOL), both mentally and socially [2–5].
As the need for an appropriate QOL assessment for
patients with IBD is increasing, a questionnaire survey of
IBD patients, the IMPACT survey was conducted between
2010 and 2011 in 25 European countries under the initia-
tive of the European Federation of Crohn’s and Ulcerative
Colitis Associations (EFCCA) [6, 7]. The European
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IMPACT survey studied IBD treatment and the impact of
IBD on patients’ lives and social activities based on survey
responses from 4670 patients with IBD.
Similar to the European IMPACT survey, we conducted
a survey in Japan; the results are reported here. The aim of
this survey was to investigate IBD treatment in Japan and
the impact of IBD on patients’ lives and social activities.
Also, we compared the results between the subgroups of
patients with UC and patients with CD.
Methods
IMPACT survey
The questionnaire is a Japanese translation of the English
version originally developed by the EFCCA and used in the
European IMPACT survey (http://www.efcca.org/index.
php/our-activities/ended-projects/51-join-the-fight-against-
ibd-project). The English version of the European
IMPACT survey questionnaire was developed by the
EFCCA, with the support of AbbVie Inc. (North Chicago,
IL, USA), and was reviewed by health informaticians. The
Japanese translation was examined by one of the authors
(F.U.) before its distribution to patients by mail and online.
The questionnaire consists of 52 questions divided into
six categories: (1) your experience with IBD, (2) health-
care, (3) the impact that IBD has on your life, (4) overall
work impact, (5) overall life impact, and (6) the role of
patient organizations. Many of the questions were sourced
from validated, published, and peer-reviewed academic
surveys or from national IBD association surveys con-
ducted in the past.
Subjects and methods
The questionnaire survey was conducted via mail or online
with the support of the IBD Network, a patient association
in Japan, during the period from 1 June 2013 to 31 January
2014. The answers were anonymous and the questionnaires
were handled in such a way that personal information was
not linked to patient data. Participants were required to be
IBD patients, but were otherwise not excluded by any
characteristics, such as age or sex. In most questions,
participants were allowed to tick one applicable option.
The online survey recruited patients with IBD nation-
wide who belong to the IBD Network. The IBD Network
posted the information on its website and distributed leaf-
lets to its patient members to disseminate the survey
information. To avoid duplication as much as possible,
each participant was required to register his or her e-mail
address; a website link was sent to guide the participant to
the questionnaire form. The survey data were managed by
the EFCCA. The paper survey was sent to 100 patients who
belong to the IBD Network. Survey collection and aggre-
gation were performed by Sunplanet Co., Ltd. (Tokyo,
Japan). The surveys collected by Sunplanet were translated
into English and sent to the EFCCA.
Data analysis was outsourced from the EFCCA to a
research consultant, Survey Solutions Ltd. (Teddington,
Middlesex, UK). The analysis results sent to the EFCCA
were forwarded to us for interpretation. Each participant
gave his or her permission to use the survey data for




Responses were obtained from 172 patients with IBD.
Ninety-eight online and 74 paper surveys were collected;
the retrieval rate was 74 % for the paper surveys. The
respondents consisted of 84 patients with UC, 83 patients
with Crohn’s disease, one patient with unclassifiable dis-
ease and four patients who did not answer this question
(Table 1, Q1). In all, 114 participants were male and 55
were female; three participants did not answer this ques-
tion. The majority of respondents (94 patients) were in the
35- to 54-year-old age group. Regarding disease activity,
79 patients (45.9 %) were in remission, 55 patients
(32.0 %) were having periodic flare-ups and 20 patients
(11.6 %) had chronically active disease (Table 1, Q16).
Patient experience with IBD
The time between noticing the first symptoms and receiv-
ing a final diagnosis was less than 6 months for 74 patients
(43.0 %), representing the most common response. A final
diagnosis was made within 1 year for 99 patients (57.6 %).
Conversely, it took 5 years or longer to arrive at a final
diagnosis for 31 patients (18.0 %) (Fig. 1, Q2). The time
between noticing IBD-related symptoms and seeing an IBD
specialist was less than 6 months for 77 patients (44.8 %),
representing the most common response. The majority of
patients (100 patients; 58.1 %) saw a specialist within
1 year (Fig. 2, Q3).
Healthcare
Among the respondents, 82 patients (47.7 %) did not have
a history of surgery for IBD, while 24 patients (14.0 %)
had undergone one surgery and 63 patients (36.6 %) had
underwent two or more surgeries (Table S1, Q6).
Regarding patient satisfaction with operative outcome, 46
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patients were very or somewhat satisfied (Table 2, Q7),
accounting for 52.9 % of the 87 patients who underwent
surgery at least once. Regarding hospitalisation in the past
5 years, 60 patients (34.9 %) were not hospitalised at all,
36 patients (20.9 %) spent 1–30 days in the hospital, 44
patients (25.6 %) spent 31–100 days in the hospital and 20
patients (11.6 %) had been hospitalised for more than
100 days (Table S1, Q8).
Aminosalicylates were the most commonly used medi-
cations; 131 patients (76.2 %) were currently receiving
aminosalicylates at the time of the survey and 26 patients
(15.1 %) had received aminosalicylates in the past.
Regarding other concomitant medications, 28 patients
(16.3 %) were currently being treated with corticosteroids
at the time of the survey and 94 patients (54.7 %) had been
treated with corticosteroids in the past; 45 patients
(26.2 %) were being treated with immunomodulators at the
time of the survey and 33 patients (19.2 %) had been
treated with immunomodulators in the past; 58 patients
(33.7 %) were currently being treated with biologic drugs
and 15 patients (8.7 %) had been treated with biologic
drugs in the past. There were eight patients (4.7 %) who
were not taking any medication at the time of the survey
(Fig. 3, Q9).
Approximately half of the respondents were satisfied
with their current IBD treatment plan; 24 patients (14.0 %)
were very satisfied and 60 patients (34.9 %) were some-
what satisfied (Table 2, Q10). There were 147 patients
(85.5 %) who reported that they had access to a gastroen-















No answer 2 1.7
Q1 type of IBD
Crohn’s disease 83 48.3
Ulcerative colitis 84 48.8
Unclassified 1 0.6
No answer 4 2.3
Q16 disease activity
In remission/not flaring 79 45.9
Chronically active 20 11.6
Active periodic flare-up 55 32.0
Not applicable/don’t know 3 1.7
IBD inflammatory bowel disease
Fig. 1 How long after you first began to notice symptoms (that you
now recognise as related to IBD) did it take to receive your final
diagnosis? (Q2, N = 172). IBD inflammatory bowel disease
Fig. 2 How long after your IBD-related symptoms began did it take
for you to first see a specialist (e.g. gastroenterologist, nurse, IBD




Table 2 Satisfaction with treatment and communication with healthcare professionals (N = 172)
No. %
Q7 How satisfied are you with the outcomes of your operation(s)?
Very satisfied 18 10.5
Somewhat satisfied 28 16.3
Neither satisfied nor dissatisfied 25 14.5
Somewhat dissatisfied 11 6.4
Very dissatisfied 4 2.3
Not applicable/don’t know 69 40.1
No answer 17 9.9
Q10 Overall, how satisfied are you with your current treatment plan for IBD?
Very satisfied 24 14.0
Somewhat satisfied 60 34.9
Neither satisfied nor dissatisfied 55 32.0
Somewhat dissatisfied 16 9.3
Very dissatisfied 5 2.9
Not applicable/don’t know 0 0.0
No answer 12 7.0
Q12 How often, after an appointment with a gastroenterologist, do you wish that he or she should have asked you more probing questions to better
understand your disease status?
Always (100 % of the time) 9 5.2
Most of the time (75–99 %) 15 8.7
Much of the time (50–74 %) 18 10.5
Sometimes (25–49 %) 76 44.2
Hardly ever/never (less than 25 % of the time) 46 26.7
Not applicable/don’t know 5 2.9
No answer 3 1.7
Q13 How often, after an appointment with a gastroenterologist, do you feel you did not get to tell the doctor something about your IBD that may have been
important?
Always (100 % of the time) 4 2.3
Most of the time (75–99 %) 11 6.4
Much of the time (50–74 %) 16 9.3
Sometimes (25–49 %) 48 27.9
Hardly ever/never (less than 25 % of the time) 75 43.6
Not applicable/don’t know 11 6.4
No answer 7 4.1
Q14 Do you believe that you have adequate access to your IBD professional? For example, can you get an appointment to see your IBD healthcare
professional on a timely basis?
Yes 136 79.1
No 20 11.6
Don’t know 14 8.1
No answer 2 1.2
Q15d Which professional(s) do you feel best understands the full picture of how IBD impacts your life—not just the medical problem? (Tick all that apply)
Applicable, No. (%) Not applicable, No. (%) No answer, No. (%)
Specialists/gastroenterologist 107 (62.2) 62 (36.0) 3 (1.7)
General physician/clinic 32 (18.6) 137 (79.7) 3 (1.7)
Nurse 34 (19.8) 135 (78.5) 3 (1.7)
Counsellor or psychologist 5 (2.9) 164 (95.3) 3 (1.7)
Other 7 (4.1) 162 (94.2) 3 (1.7)
Don’t know/not applicable 36 (20.9) 133 (77.3) 3 (1.7)
IBD inflammatory bowel disease
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terology specialist at the clinic where they were being
treated (Q11, data not shown).
After an appointment with a gastroenterologist, 118
patients (68.6 %) sometimes (or more often) thought that
the physician should have asked more probing questions to
better understand their disease status (Table 2, Q12). In
addition, 79 patients (45.9 %) sometimes (or more often)
felt that they did not get to tell the physician something
potentially important about their IBD status (Table 2,
Q13).
Among the respondents, 136 patients (79.1 %) felt that
access to their IBD professional was adequate (Table 2,
Q14). In response to questions about communication with
medical professionals, 114 patients (66.3 %) answered that
the best range of options for communication was available
with an IBD specialist/gastroenterologist, 38 patients
(22.1 %) selected a nurse, 31 patients (18.0 %) selected a
general physician/clinic and one patient (0.6 %) selected a
counsellor (Q15a, data not shown). With regard to medical
professionals who best understand not just the medical
problems but also the entire picture of how IBD impacts
their life, 107 patients (62.2 %) chose an IBD special-
ist/gastroenterologist, 34 patients (19.8 %) chose a nurse,
32 patients (18.6 %) chose a general physician/clinic and
five patients (2.9 %) chose a counsellor (Table 2, Q15d).
Impact that IBD has on your life
During the current or most recent flare, 85 patients
(49.4 %) sometimes or more frequently had to cancel or
reschedule an engagement or meeting because of IBD
(Table 3, Q19). During the current or most recent period
not experiencing a flare, 90 patients (52.3 %) hardly ever/
never had to cancel or reschedule an engagement or
meeting because of IBD, and 50 patients (29.1 %) had to
sometimes or more frequently cancel or reschedule an
engagement or meeting because of IBD (Table S2, Q27).
During the current or most recent flare, 84 patients
(48.8 %) did not experience bleeding from the gastroin-
testinal tract and 84 patients (48.8 %) experienced bleeding
at least 1 day a week. Among those who experienced
bleeding, 42 patients (24.4 %) had bleeding every day
(Table S2, Q20). During the current or most recent period
not experiencing a flare, 136 patients (79.1 %) did not
experience bleeding from the gastrointestinal tract and 31
patients (18.0 %) experienced bleeding at least 1 day a
week. Among those who experienced bleeding, seven
patients (4.1 %) had bleeding every day (Table S2, Q28).
During the current or most recent flare, 51 patients
(29.7 %) did not experience cramping pain in the abdomen
and 116 patients (67.4 %) experienced abdominal pain at
least 1 day a week. Of the patients experiencing abdominal
pain, 57 patients (33.1 %) experienced abdominal pain
every day (Table S2, Q21). During the current or most
recent period not experiencing a flare, 99 patients (57.6 %)
did not experience cramping pain in the abdomen and 69
patients (40.1 %) experienced abdominal pain at least
1 day a week. Of the patients experiencing abdominal pain,
12 (7.0 %) experienced abdominal pain every day
(Table S2, Q29).
During the current or most recent flare, 40 patients
(23.3 %) did not feel tired, weak or worn out and 129
Fig. 3 Which of the following
types of medicine are you taking
right now? Or, have you taken
in the past? (Q9, N = 172)
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Table 3 Impact of IBD on work and life (N = 172)
No. %
Q18 How many flare-ups would you say you have experienced in the last 2 years?











More than 10 4 2.3
My condition is always (chronically) actively flaring 20 11.6
No answer 5 2.9
Q19 During your current or most recent flare, how often do/did you have to cancel or reschedule an engagement, meeting, etc. because of
your IBD?
(Select the option that most closely represents your own experience)
Always (100 % of the time) 12 7.0
Most of the time (75–99 %) 12 7.0
Much of the time (50–74 %) 24 14.0
Sometimes (25–49 %) 37 21.5
Hardly ever/never (less than 25 % of the time) 56 32.6
Not applicable/don’t know 27 15.7
No answer 4 2.3
Q36 Please indicate any adjustments you have made to your working life, purely to avoid the need to take sick days as a result of your IBD:
I have not made any such adjustments 102 59.3
Working flexible hours 14 8.1
Working from home 17 9.9
Working part-time 24 14.0
No answer 15 8.7
Applicable, No. (%) Not applicable, No. (%) No answer, No. (%)
Q38 If you have been absent from work due to your IBD, what was this primarily due to? (Tick all that apply)
Hospital/emergency department visit 39 (22.7) 116 (67.4) 17 (9.9)
Doctor appointment 87 (50.6) 68 (39.5) 17 (9.9)
Incontinence or fear of incontinence 13 (7.6) 142 (82.6) 17 (9.9)
Cramping or painful abdomen 40 (23.3) 115 (66.9) 17 (9.9)
Fear of toilet frequency interfering with work activities 28 (16.3) 127 (73.8) 17 (9.9)
Fear of toilet frequency bringing attention to my condition
from colleagues
6 (3.5) 149 (86.6) 17 (9.9)
Fatigue and/or not enough energy to get through the day 54 (31.4) 101 (58.7) 17 (9.9)
Worry about gas pressure, discomfort 20 (11.6) 135 (78.5) 17 (9.9)
Worry/fear of potential for embarrassment 7 (4.1) 148 (86.0) 17 (9.9)
Rectal/anal pain or burning 8 (4.6) 147 (85.5) 17 (9.9)
Volume of blood in bleeding episode 13 (7.6) 142 (82.6) 17 (9.9)
I have never been absent from work due to IBD 8 (4.6) 147 (85.5) 17 (9.9)





Q39 Have you received or heard of complaints or unfair comments from your superiors and/or colleagues about your performance at work in
relation to your illness?
No 112 65.1
Yes 46 26.7
No answer 14 8.1
Q40 Do you believe you have been discriminated in the workplace as a direct result of your IBD?
No 120 69.8
Yes 38 22.1
No answer 14 8.1
Applicable, No. (%) Not applicable, No. (%) No answer, No. (%)
Q41 How does IBD affect your behaviour at work? (Tick all that apply)
I am quiet or quieter during meetings 24 (13.5) 135 (78.5) 13 (7.6)
I cancel my attendance at meetings at the last minute 12 (7.0) 147 (85.5) 13 (7.6)
I do not participate in work social activities 51 (29.7) 108 (62.8) 13 (7.6)
I am irritable at work 19 (11.0) 140 (81.4) 13 (7.6)
I am less motivated in my work 38 (22.1) 121 (70.3) 13 (7.6)
My IBD does not affect my behaviour at work 46 (26.7) 113 (65.7) 13 (7.6)
Not applicable/other 42 (24.4) 117 (68.0) 13 (7.6)
No. %
Q42 How much do you agree with the following statements? I believe that IBD has negatively affected my career path, opportunities for
advancement, income and/or earning potential
Strongly agree 44 25.6
Agree 35 20.3
Neither agree nor disagree 39 22.7
Disagree 8 4.7
Strongly disagree 7 4.1
Not applicable 27 15.7
No answer 12 7.0
Q43 I have lost a job (or had to quit a job) because of my IBD
Strongly agree 39 22.7
Agree 22 12.8
Neither agree nor disagree 27 15.7
Disagree 7 4.1
Strongly disagree 7 4.1
Not applicable 58 33.7
No answer 12 7.0
Q47 My IBD has negatively affected my ability to perform to my full potential in an educational setting
Strongly agree 13 7.6
Agree 40 23.3
Neither agree nor disagree 49 28.5
Disagree 17 9.9
Strongly disagree 15 8.7
Not applicable 31 18.0
No answer 7 4.1
IBD inflammatory bowel disease
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patients (75.0 %) felt tired at least 1 day a week. Of the
patients who felt tired, weak or worn out, 59 patients
(34.3 %) felt tired every day (Table S2, Q22). During the
current or most recent period not experiencing a flare, 69
patients (40.1 %) did not feel tired, weak or worn out and
99 patients (57.6 %) felt tired at least 1 day a week. Of the
patients who felt tired, weak or worn out, 18 (10.5 %) felt
tired every day (Table S2, Q30).
During the current or most recent flare, 56 patients
(32.6 %) did not feel a sudden uncontrollable urge for a
bowel movement and 113 patients (65.7 %) had bowel
urgency at least 1 day a week. Of those experiencing bowel
urgency, 49 patients (28.5 %) had bowel urgency every day
(Table S2, Q23). During the current or most recent period
not experiencing a flare, 91 patients (52.9 %) did not feel a
sudden uncontrollable urge for a bowel movement and 77
patients (44.8 %) had bowel urgency at least 1 day a week.
Of the patients experiencing bowel urgency, 14 (8.1 %)
had bowel urgency every day (Table S2, Q31).
During the current or most recent flare, 26 patients
(15.1 %) did not experience runny stools or an episode of
diarrhoea and 128 patients (74.4 %) experienced diarrhoea
at least once a day. Of the patients experiencing diarrhoea,
48 patients (27.9 %) had diarrhoea 5–10 times a day,
representing the most common answer (Table S2, Q24).
During the current or most recent period not experiencing a
flare, 62 patients (36.0 %) did not experience runny stools
or an episode of diarrhoea and 99 patients (57.6 %) expe-
rienced diarrhoea at least once a day. Of the patients
experiencing diarrhoea, 44 (25.6 %) had diarrhoea one or
two times a day, representing the most common answer
(Table S2, Q32).
During the current or most recent flare, 69 patients
(40.1 %) sometimes or more frequently had to abruptly
stop or leave a conversation, meeting or activity because of
symptoms of IBD (Table S2, Q25). During the current or
most recent period not experiencing a flare, 36 patients
(20.9 %) sometimes or more frequently had to abruptly
stop or leave a conversation, meeting or activity because of
symptoms of IBD (Table S2, Q33).
Eighty-one patients (47.1 %) felt that their lives were
significantly or somewhat negatively affected by symptoms
of IBD, even between flares (Table S2, Q26). During a
period not experiencing a flare, 126 patients (73.3 %)
worried sometimes or more frequently about when the next
flare would occur. Of these patients, 35 (20.3 %) worried
about the next flare all the time (Table S2, Q34).
Work impact
Regarding the overall work impact, 124 patients (72.1 %)
feel stressed or pressured about taking sick time from work
because of IBD (Table S2, Q35). Fifty-five patients
(32.0 %) made adjustments in their working life to avoid
taking sick days: 14 patients (8.1 %) work flexible hours,
17 patients (9.9 %) work from home and 24 patients
(14.0 %) work part-time (Table 3, Q36). There were 111
patients (64.5 %) who had taken at least one sick day from
work because of IBD in the past year; 25 patients (14.5 %)
had been absent for more than 25 days (Table S2, Q37).
The most common reasons for being absent from work
were a doctor’s appointment (87 patients; 50.6 %), fatigue
and/or not enough energy to get through the day (54
patients; 31.4 %), cramping or painful abdomen (40
patients; 23.3 %) and emergency department visits (39
patients; 22.7 %). Patients were also absent because of
worries about symptoms instead of actually having symp-
toms, such as a fear of toilet frequency interfering with
work (28 patients; 16.3 %) and worries about gas pressure
or discomfort (20 patients; 11.6 %) (Table 3, Q38).
Forty-six patients (26.7 %) had received or heard com-
plaints or unfair comments from superiors and/or col-
leagues about their work performance in relation to their
illness (Table 3, Q39). Some felt they were discriminated
in the workplace as a direct result of IBD (38 patients;
22.1 %) (Table 3, Q40). The most commonly reported
impact of IBD on workplace behaviour was nonparticipa-
tion in work social activities (51 patients; 29.7 %), fol-
lowed by less motivated at work (38 patients; 22.1 %),
being quiet during meetings (24 patients; 13.5 %) and
irritability at work (19 patients; 11.0 %). However, 46
patients (26.7 %) answered that their behaviours at work
were unaffected by IBD (Table 3, Q41). As many as 79
patients (45.9 %) felt that IBD negatively affected their
career path, opportunities for advancement, income and/or
earning potential (Table 3, Q42). Sixty-one patients
(35.5 %) felt that they had lost a job or had to quit a job
because of IBD (Table 3, Q43).
Overall life impact
Regarding the impact of IBD on overall life, 44 patients
(25.6 %) felt that IBD had prevented them from pursuing
an intimate relationship, and 38 patients (22.1 %) felt that
IBD had caused an intimate relationship to end. In addition,
40 patients (23.3 %) felt that IBD had prevented them from
making and/or keeping friends (Table S3, Q44–46).
Fifty-three patients (30.8 %) reported that IBD had
negatively affected their ability to perform to their full
potential in an educational setting (Table 3, Q47). In all,
108 patients (62.8 %) frequently considered the availability
of toilets when planning to attend an event or meeting, 124
patients (72.1 %) worried about the ready availability of a
toilet when going somewhere new, 30 patients (17.4 %)
kept a list of clean, accessible toilets and considered it
when leaving home, 58 patients (33.7 %) had to be rude to
J Gastroenterol
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people at times in order to gain access to a toilet to prevent
an accident, 10 patients (5.8 %) reported that other people
had sometimes joked about them when they urgently nee-
ded a toilet and 43 patients (25.0 %) frequently woke from
sleeping as a result of pain from IBD (Table S4, Q48).
The first time they met another person with IBD, 61
patients (35.5 %) felt more optimistic, positive and/or
hopeful about the future, 14 patients (8.1 %) felt more
pessimistic, negative and/or less hopeful about the future
and 88 patients (51.2 %) felt neither more optimistic nor
more pessimistic (Table S4, Q49).
The majority of the respondents (130 patients; 75.6 %)
were engaged in an IBD patient association (Table S4,
Q50); 73 patients (42.4 %) attend local or national patient
meetings, 108 patients (62.8 %) are members of their
national IBD association, 73 patients (42.4 %) receive
patient information leaflets from their national IBD asso-
ciation, 13 patients (7.6 %) call a helpline or e-mail their
national IBD association, 58 patients (33.7 %) subscribe to
newsletters or magazines from their national IBD associ-
ation, 39 patients (22.7 %) volunteer to help their national
IBD association, 13 patients (7.6 %) help their national
IBD association with fundraising, 38 patients (22.1 %)
became a leader or joined a committee within their national
IBD association and two patients (1.2 %) became an
EFCCA delegate or worked within an EFCCA project team
(Table S4, Q51). Among the respondents, 87 patients
(50.6 %) felt that being part of the patient association
improved their life in general as someone with IBD
(Table S3, Q52).
Subgroup analysis: ulcerative colitis vs. Crohn’s
disease
In a subgroup analysis, we compared the results between
respondents with UC (84 patients) and CD (83 patients).
Regarding disease activity, 38.1 % (32/84) and 55.4 % (46/
83) of respondents, respectively, were in remission, 35.7 %
(30/84) and 30.1 % (25/83) were having periodic flare-ups
and 11.9 % (10/84) and 12.0 % (10/83) had chronically
active disease. Table 4 shows the results of the questions
for which the differences in the proportions between the
two groups exceeded 20 %.
Patients with UC were diagnosed or visited a specialist
within a relatively short time after first noticing symptoms,
and patients with UC experienced more bleeding from the
gastrointestinal tract during a flare than patients with CD.
Forty-seven patients (56.0 %) with UC were diagnosed
within 6 months of first noticing symptoms, whereas this
was the case for only 27 patients (32.5 %) with CD
(Table 4, Q2). Forty-nine patients (58.3 %) with UC saw a
specialist within 6 months of first noticing symptoms,
whereas this was the case for only 28 patients (33.7 %)
with CD (Table 4, Q3). During the current or most recent
flare, 35 patients (41.7 %) with UC had bleeding every day,
as opposed to seven patients (8.4 %) with CD (Table 4,
Q20). During the current or most recent period not expe-
riencing a flare, 40 patients (47.6 %) with UC did not
experience runny stools or an episode of diarrhoea, as
opposed to 21 patients (25.3 %) with CD (Table 4, Q32).
Compared to patients with CD, patients with UC were
more concerned about the side effects of steroids, and
fewer patients with UC had a history of hospitalization or
surgery. Forty-two patients (50.0 %) with UC were con-
cerned about the long-term effects of steroids on their
health, as opposed to 19 patients (22.9 %) with CD
(Table 4, Q5-2). Regarding surgery, 64 patients (76.2 %)
with UC and 17 patients (20.5 %) with CD had never
undergone surgery; four patients (4.8 %) with UC had
undergone five or more surgeries, as opposed to 15 patients
(18.0 %) with CD (Table 4, Q6). Regarding hospitalization
in the past 5 years, 39 patients (46.4 %) with UC and 21
(25.3 %) with CD had no hospital stays (Table 4, Q8).
Regarding medications, fewer patients with UC were tak-
ing biologic drugs at the time of the survey compared to
patients with CD (8.3 % [7/84] vs. 60.2 % [50/83])
(Table 4, Q9).
Patients with CD tended to have had a longer time since
their last flare at the time of the survey, though they also
seemed to feel more tired during the flare and have been
absent from work because of IBD more often. Forty-three
patients (51.8 %) with CD experienced their last flare more
than 1 year ago, compared to 24 patients (28.6 %) with UC
(Table 4, Q17). During the current or most recent flare, 39
patients (47.0 %) with CD felt tired every day, as opposed
to 20 patients (23.8 %) with UC (Table 4, Q22). Sixty-four
patients (77.1 %) with CD had taken at least one sick day
from work because of IBD in the past year, as opposed to
46 patients (54.8 %) with UC (Table 4, Q37).
Discussion
Our survey results indicate that the lives and social activ-
ities of patients with IBD are affected by the deterioration
of QOL due to IBD and its symptoms. In Japan, several
previous studies have also investigated QOL and the
impact of IBD on patients’ lives and social activities and
similarly demonstrated deterioration in QOL associated
with IBD [8–17]. Our present survey is unique in that we
used a questionnaire that comprised basically the same set
of questions as the European IMPACT survey to allow
direct comparison between the Japanese and European
survey results. Our survey results will not only help
improve medical treatment and care for patient with IBD in
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Table 4 Comparison of ulcerative colitis and Crohn’s disease: the items for which the differences between the groups were more than 20 %
Ulcerative colitis (N = 84) Crohn’s disease (N = 83)
No. (%) No. (%)
Q2 How long after you first began to notice symptoms (that you now recognise as related to IBD) did it take to receive your final
diagnosis?
Less than 6 months 47 (56.0) 27 (32.5)
6 months–1 year 12 (14.3) 12 (14.5)
Over 1 to 5 years 14 (16.7) 23 (27.7)
Over 5 to 10 years 2 (2.4) 10 (12.0)
More than 10 years 8 (9.5) 11 (13.3)
Not applicable 1 (1.2) 0 (0.0)
Q3 How long after your IBD-related symptoms began did it take for you to first see a specialist (e.g. gastroenterologist, nurse, IBD
specialist) who was familiar with IBD?
Less than 6 months 49 (58.3) 28 (33.7)
6 months–1 year 11 (13.1) 12 (14.5)
Over 1 to 5 years 18 (21.4) 27 (32.5)
Over 5 to 10 years 3 (3.6) 11 (13.3)
More than 10 years 2 (2.4) 4 (4.8)
Not applicable 1 (1.2) 1 (1.2)
Q5-2 I am concerned about the long-term effects of steroids on my health
Yes 42 (50.0) 19 (22.9)
No 41 (48.8) 63 (75.9)
Not applicable 1 (1.2) 1 (1.2)
Q6 How many surgical operations have you had for IBD and IBD-related medical problems?
0 64 (76.2) 17 (20.5)
1–4 16 (19.0) 51 (61.4)
5–10 4 (4.8) 14 (16.9)
More than 10 0 (0.0) 1 (1.2)
Not applicable 0 (0.0) 0 (0.0)
Q8 Over the last 5 years, how many days in total have you been hospitalised because of IBD symptoms? (Please type in number of days)
0 days 39 (46.4) 21 (25.3)
1–10 6 (7.1) 7 (8.4)
11–50 18 (21.4) 24 (28.9)
51–100 8 (9.5) 15 (18.1)
101–200 6 (7.1) 5 (6.0)
200? 2 (2.4) 8 (9.6)
Not applicable 5 (6.0) 3 (3.6)



















Aminosalicylates 65 (77.4) 13 (15.5) 6 (7.1) 64 (77.1) 13 (15.7) 6 (7.2)
Corticosteroids 17 (20.2) 47 (56.0) 20 (23.8) 10 (12.0) 47 (56.6) 26 (31.3)
Drugs that affect the immune
system
18 (21.4) 14 (16.7) 52 (61.9) 27 (32.5) 18 (21.7) 38 (45.8)
‘‘Biologic’’ drugs 7 (8.3) 5 (6.0) 72 (85.7) 50 (60.2) 10 (12.0) 23 (27.7)
Other 17 (20.2) 4 (4.8) 63 (75.0) 23 (27.7) 6 (7.2) 54 (65.1)
I don’t take any medications 4 (4.8) 0 (0.0) 80 (95.2) 3 (3.6) 1 (1.2) 79 (95.2)
I take something but don’t know
what it is
4 (4.8) 1 (1.2) 79 (94.0) 2 (2.4) 0 (0.0) 81 (97.6)
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Japan but also provide useful information for reviewing
medical practice for IBD in each country in Europe.
Our study results were similar to those of the European
IMPACT survey for most components, including the time
to definitive diagnosis, use of medications and life impact
of IBD [6, 7]. Despite differences in race, life environment
and medical system, the results of our study and the
European IMPACT study likely reflect common trends in
IBD patients. As in the European IMPACT study, the
Japanese survey points out several issues: (1) communi-
cation between medical specialists and patients can be
further improved, (2) IBD patients often have to take sick
days from work and have psychological fear at work
because of their illness, (3) IBD has a significant impact on
daily life, including constant concern about toilets and
difficulty building intimate relationships, and (4) IBD
interferes with learning. Patients with IBD have unmet
needs; the goal is to improve medical care and the social
support system for patients with IBD in Japan.
While the Japanese results were generally similar to the
European survey results [6], there were several differences.
First, the proportion of patients who were somewhat or
very satisfied with the outcomes of IBD-related surgical
operations was lower in Japan (52.9 %) than in Europe
(72.9 %). This may be partly attributed to the higher per-
centage of Japanese patients with surgical complications
(20.3 %) compared with European patients (14.6 %). In
addition, Japanese patients were less satisfied with their
current treatment plan for IBD than European patients
(48.8 vs 70.3 %). Because the answers to questions about
the adequateness of communication with medical profes-
sionals were similar between Japanese and European
patients, the lower level of satisfaction in Japanese patients
cannot be attributed solely to inadequate communication,
Table 4 continued
No. (%) N (%)
Q17 When was your last flare (before this one if you are currently experiencing one)?
Less than 6 months ago 27 (32.1) 20 (24.1)
Over 6–12 months ago 10 (11.9) 8 (9.6)
More than 12 months ago 24 (28.6) 43 (51.8)
Not applicable 23 (27.4) 12 (14.5)
Q20 During your current or most recent flare, how many days in a week do/did you experience bleeding from your gastrointestinal tract?
(Select the option that most closely represents your own experience)
0 day 30 (35.7) 53 (63.9)
1–3 days 13 (15.5) 19 (22.9)
4–6 days 6 (7.1) 2 (2.4)
7 days 35 (41.7) 7 (8.4)
Not applicable 0 (0.0) 2 (2.4)
Q22 During your current or most recent flare, how many days in a week do/did you feel tired, weak or worn out? (Select the option that
most closely represents your own experience)
0 day 23 (27.4) 17 (20.5)
1–3 days 29 (34.5) 16 (19.3)
4–6 days 12 (14.3) 10 (12.0)
7 days 20 (23.8) 39 (47.0)
Not applicable 0 (0.0) 1 (1.2)
Q32 During your current or most recent period NOT experiencing a flare, how many runny stools or episodes of diarrhoea do/did you
experience in the course of a typical day?
(Select the option that most closely represents your own experience)
Did not experience 40 (47.6) 21 (25.3)
1–2 times a day 24 (28.6) 19 (22.9)
More than 2 times a day 14 (16.7) 40 (48.2)
Not applicable 6 (7.1) 3 (3.6)
Q37 In the past year, how many days have you been absent from work for reasons related to your IBD?
0 day 29 (34.5) 17 (20.5)
1 day or more 46 (54.8) 64 (77.1)
Not applicable 9 (10.7) 2 (2.4)
IBD inflammatory bowel disease
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indicating the presence of some other issue with the med-
ical treatment itself or the medical environment in Japan.
Although a greater percentage of Japanese patients had
not been hospitalised in the past 5 years compared with
European patients (34.9 vs 15.4 %), more Japanese patients
had been hospitalised for more than 10 days compared
with European patients (50.0 vs 2.1 %). In addition,
11.6 % of Japanese patients remained in the hospital for
more than 100 days, indicating that Japanese patients, once
hospitalised, tend to remain in the hospital longer or return
frequently.
Regarding healthcare professionals who are available
for communication or who have the greatest influence on
IBD patients, fewer Japanese patients named a counsellor
or clinical psychologist compared with European patients.
This indicates that counsellors and clinical psychologists
are not sufficiently positioned in Japanese hospitals or are
not adequately involved with patients with IBD. As shown
in our survey results, IBD patients suffer a great deal of
mental strain from their illness; thus, we will have to
reconsider how counsellors and clinical psychologists can
be involved in their care.
Finally, slightly more Japanese patients with IBD seem
to feel stressed or pressured about taking sick time from
work because of IBD compared with European patients
(72.1 vs 60.5 %). Because Japanese patients do not seem to
have particularly high external pressure, such as unfair
treatment, discrimination and career path impediment due
to IBD, Japanese patients may be too self-critical compared
with European patients. Therefore, mental support will be
necessary to promote the social participation of patients
with IBD in Japan.
Subgroup analysis comparing UC and CD revealed
characteristics of each disease based on the differences
between the subgroups. UC is associated with more fre-
quent anaemia, bloody stool, and mucous and bloody stool
compared with CD, for which the frequency of bloody
stool is less frequent. This is attributed to the characteris-
tics of CD, in which lesions do not easily bleed and the
rectum is less frequently affected. Thus, the present study
results are consistent with the pathology of these conditions
[18]. Patients with UC tend to develop intestinal haemor-
rhage on a daily basis during flare-ups, and many of them
visited a specialist and received a definitive diagnosis at a
relatively early phase. As described above, this is due to the
pathological characteristics of UC, with patients having
bloody stool and mucous and bloody stool more often
compared with CD. On the other hand, patients with CD
tend to have more adverse influences in their daily lives,
such as absence from work, which seems to be due to
malaise during flare-ups. However, the duration of a flare-
up was not long in many patients. UC affects areas near the
intestinal lumen, from the mucosal layer to the submucosal
layer, representing shallow inflammation. In contrast, CD
causes deeper inflammation, often reaching the muscle
layer. UC, with shallower inflammation, is generally
acknowledged as a milder enterocolitis than CD, which
causes deeper inflammation. Thus, CD has a greater impact
on labour productivity compared with UC, from a patho-
logical point of view [19–21].
With regard to the therapy, many patients with UC
expressed concern about the long-term use of steroids,
while the majority of patients with CD received aggressive
therapy, including hospitalization, surgical intervention
and treatment with biological agents. This reflects the
current UC treatment practice that frequently recommends
steroids as part of remission induction therapy according to
clinical practice guidelines (Japan, USA and EU) [22–24].
It should be noted that steroids are not suitable for main-
tenance therapy but are highly effective in remission
induction. In the real world, patients with steroid depen-
dency are treated with steroids for an extended period, and
the associated adverse reactions are a concern [25, 26].
Although our survey offers a broad perspective, there
are several limitations to this study. First, the survey par-
ticipation was free and therefore it was inherently associ-
ated with a bias in respondent selection. Second, while not
all respondents were attending patient associations, survey
recruitment was conducted only within the reach of infor-
mation from the IBD Network patient association and the
respondents may not include those who were not closely
related with that association. Third, the majority of
respondents were acquired through the online survey site,
and the results may not represent those who do not have
access to the Internet. Fourth, the Japanese survey sample
size was smaller than that of the European IMPACT sur-
vey. However, our survey achieved the minimum target of
100, which was also the target in the European survey [6].
Finally, several questions may have had a recall bias, as
patients had to recall situations in the past.
Accessibility to the Internet or the IBD network may
vary depending upon a patient’s awareness of treatment
options and their environment; therefore, our survey may
not necessarily reflect the current status of Japanese
patients with IBD. Providing patients with a questionnaire
during their medical visits, i.e. administering the survey via
a healthcare professional, would better reflect their current
situation across a broader demographic.
Conclusions
Our survey results indicate that lives and social activities of
IBD patients in Japan are affected by the deterioration of
QOL due to IBD and its symptoms. Information on the
unmet needs of Japanese patients with IBD may help to
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provide sufficient medical and administrative support,
improve working and educational environments, and
increase the awareness of healthcare providers in order to
bridge communication gaps between patients and
physicians.
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